Glaxosmi. Pharma
Drug Manufacturers - General · GLAXO
Large CapHealthcareMature Stable
Bhushan Akshikar
Managing Director · Pragmatic
Company DNA
Bureaucratic
About
Glaxosmi. Pharma is a Large Cap company in the Healthcare sector, listed on NSE as GLAXO. With a market cap of ₹43K Cr and revenue of ₹4K Cr, it is currently in the Mature Stable phase. Known for its Bureaucratic culture and Traditionalist approach to innovation, the company operates at a Steady-Marathon pace. Compliance-heavy multinational pharmaceutical firm with rigorous global quality and operational standards. Its strategic mandate: Requires a shift toward agile product commercialization and specialized therapy focus to rejuvenate growth in a highly competitive pharmaceutical landscape.
FAQ
What kind of company is Glaxosmi. Pharma?
Glaxosmi. Pharma is a Large Cap Healthcare company (GLAXO) in the Mature Stable phase with a market cap of ₹43K Cr. It is classified as Bureaucratic in culture.
What is Glaxosmi. Pharma's culture and work environment like?
Glaxosmi. Pharma has a Bureaucratic culture with Traditionalist innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: Mass-Consumer. Compliance-heavy multinational pharmaceutical firm with rigorous global quality and operational standards.
Who leads Glaxosmi. Pharma?
Glaxosmi. Pharma is led by Bhushan Akshikar (Managing Director), a Pragmatic leader with 30 years of experience.
What are Glaxosmi. Pharma's financials?
Glaxosmi. Pharma reported revenue of ₹4K Cr in FY25 with a 5-year revenue CAGR of 4.5%. Operating margin: 29.9%. Market cap: ₹43K Cr.
Culture & Strategy
CultureBureaucratic
InnovationTraditionalist
PaceSteady-Marathon
PurposePurpose-Blended
CustomerMass-Consumer
EmployeeSteady Employer
BrandTrusted
LifecycleMature Stable
Compliance-heavy multinational pharmaceutical firm with rigorous global quality and operational standards.
Mandate
Requires a shift toward agile product commercialization and specialized therapy focus to rejuvenate growth in a highly competitive pharmaceutical landscape.
Requires a shift toward agile product commercialization and specialized therapy focus to rejuvenate growth in a highly competitive pharmaceutical landscape.
Financials
Revenue FY25₹4K Cr
PAT FY25₹928 Cr
Rev CAGR 5Y4.5%
OPM29.9%
NPM24.9%
ROE47.5%
ROCE50.6%
P/E40.2
Fwd P/E35.4
P/B24
D/E2.1
Mkt Cap₹43K Cr
Promoter75.6%
Institutional8.5%
Similar Culture
Could You Lead Glaxosmi. Pharma?
Take the Genome Benchmark →